(provided by candidate): Although Alzheimer's, Parkinson's, and Huntington's diseases have certain distinct clinical characteristics, the single protein Uch-L1 has been implicated in all three disorders. Furthermore, a common natural variant of Uch-L1 (S18Y) has been shown to provide protection from all three of these diseases. The only visible difference between Uch-L1 S18Y and the wild-type protein is that the neuroprotective variant crystallizes as a dimer, whereas the wild-type protein appears as a monomer. Uch-L1 protein makes up a substantial proportion (up to 2%) of soluble protein in the central nervous system. However, the role of Uch- L1 protein in either normal or diseased neuronal tissue is unknown. The dimerization of Uch-L1 protein will be explored in detail, and small molecules will be experimentally screened for their ability to stabilize dimeric Uch-L1. Uch-L1 dimerization will be exploited as a method to protect against neurodegenerative diseases;successful small molecules will be converted into lead compounds for oral therapeutics that can protect at-risk individuals from Parkinson's Disease. Additionally, three proteins have been found to interact with Uch-L1. Their identities will be determined and used to make new hypotheses about the role of Uch-L1 in healthy neuronal tissue. Uch-L1 will be assayed for ubiquitin hydrolase activity on any monoubiquitinated proteins that interact with it. Lastly, an irreversible inhibitor of cysteine proteases will be co-crystallized with Uch-L1 in an effort to trap and observe an active protein conformation. Uch-L1 protein is a uniquely valuable target for drug development because a common natural variant is known to protect against Parkinson's, Alzheimer's, and Huntington's diseases. However, the functions of Uch-L1 in disease development or in healthy tissue are unknown. This proposal seeks to understand the normal roles of Uch-L1 protein and to find drug-like molecules that can stabilize neuroprotective Uch-L1 and protect individuals from development of neurodegenerative diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32NS063495-02
Application #
7901064
Study Section
Special Emphasis Panel (ZRG1-F03B-H (20))
Program Officer
Sutherland, Margaret L
Project Start
2009-05-18
Project End
2012-05-17
Budget Start
2010-05-18
Budget End
2011-05-17
Support Year
2
Fiscal Year
2010
Total Cost
$59,918
Indirect Cost
Name
Brandeis University
Department
Type
Organized Research Units
DUNS #
616845814
City
Waltham
State
MA
Country
United States
Zip Code
02454